Silver Book

Silver Book Fact

AFib practice guidelines reduce direct health care costs

The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.

Zimetbaum P, Reynolds M, Ho K, Gaziano T, et al. Impact of a Practice Guideline for Patients with Atrial Fibrillation on Medical Resource Utilization and Costs. Am J Cardiol. 2003; 92(6): 677-81. http://www.ajconline.org/article/S0002-9149(03)00821-X/abstract

Reference

Title
Impact of a Practice Guideline for Patients with Atrial Fibrillation on Medical Resource Utilization and Costs
Publication
Am J Cardiol
Publication Date
2003
Authors
Zimetbaum P, Reynolds M, Ho K, Gaziano T, et al
Volume & Issue
Volume 92, Issue 6
Pages
677-81
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
  • Stroke rates among Afib patients
    In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.  
  • Effects of optimal anticoagulation among AFib patients
    If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.